Revised Prices of Anti-Cancer Medicines to Come into Effect From 9th November

Key Highlights:

• The National Pharmaceutical Pricing Authority (NPPA) capped trade margins on the Maximum Retail Price (MRP) of 137 anti-cancer drugs.
• The revised prices for these drugs will come into effect from 9th November, 2026.
• This measure is estimated to result in annual savings of ₹3,502.31 crore for consumers.
• Price reductions were reported in 1031 anti-cancer formulations, with 600 brands seeing over 50% reduction.

Detailed Insights:

• The decision was based on recommendations from an Expert Committee constituted by the Directorate General of Health Services (DGHS).
• This Trade Margin Rationalization (TMR) aims to enhance the affordability and accessibility of essential anti-cancer medicines.
• Manufacturers can still avail annual price increases as per the Drugs (Prices Control) Order, 2013, provided the maximum 30% trade margin is maintained.
• State Drug Controllers will monitor compliance, and consumers can check prices via the Pharma Sahi Daam mobile application and the NPPA website.

Key Concepts Involved:

• National Pharmaceutical Pricing Authority (NPPA): A government regulatory body that fixes and revises prices of controlled bulk drugs and formulations.
• Trade Margin Rationalization (TMR): A policy to cap the profit margin allowed to distributors and retailers on the Maximum Retail Price (MRP) of drugs.
• Drugs (Prices Control) Order, 2013: The legal framework empowering the government to control drug prices in India.